Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro.
Term Amniotic membrane is a high throughput source for multipotent Mesenchymal Stem Cells with the ability to differentiate into endothelial cells in vitro.
复制标题
术语羊膜是多能间充质干细胞的高吞吐量来源，能够在体外分化为内皮细胞。
DOI：
10.1186/1471-213x-7-11
复制
发表时间：
2007-02-21
影响因子：
--
通讯作者：
Bagnara, Gian Paolo
中科院分区：
文献类型：
--
作者：
Alviano, Francesco;Fossati, Valentina;Marchionni, Cosetta;Arpinati, Mario;Bonsi, Laura;Franchina, Michele;Lanzoni, Giacomo;Cantoni, Silvia;Cavallini, Claudia;Bianchi, Francesca;Tazzari, Pier Luigi;Pasquinelli, Gianandrea;Foroni, Laura;Ventura, Carlo;Grossi, Alberto;Bagnara, Gian Paolo
术语羊膜（AM）是间充质干细胞（MSC）的一个非常有吸引力的来源，因为这种胎儿组织通常在没有伦理冲突的情况下被丢弃，从而导致MSC回收的高效率，而无需侵入性程序。在这里，我们证实了术语AM，如先前在文献中报道的，是hMSC的丰富来源;特别地，我们通过评估这些细胞是否也可以致力于血管生成命运来进一步研究AM分化潜力。与国际细胞治疗学会的推荐一致，本文研究的间充质细胞被命名为羊膜-人间充质基质细胞（AM-hMSC）。羊膜中hMSCs的恢复率和体外扩增能力均高于骨髓基质。在流式细胞术分析中，AM-hMSC显示出免疫表型特征，即，CD 105、CD 73、CD 29、CD 44、CD 166阳性，CD 14、CD 34、CD 45阴性，与骨髓来源的MSC报道的结果一致。此外，羊膜分离的细胞经历体外成骨（von Kossa染色）、成脂（油红-O染色）、成软骨（II型胶原酶化学检测）和成肌（RT-PCR MyoD和Myogenin表达以及结蛋白免疫组织化学检测）分化。在血管生成实验中，通过体外基质胶测定检测到自发分化为内皮细胞，并且通过血管内皮生长因子（VEGF）诱导增强了这种行为。结果表明，VEGF受体1和2（FLT-1和KDR）在AM-hMSCs中表达较强，VEGF作用后内皮细胞特异性标志物FLT-1、KDR、ICAM-1表达增强，并出现CD 34和von Willebrand Factor阳性细胞。目前的研究表明，AM-hMSCs可能成为一个显着的工具，用于多种疾病组织的细胞治疗。AM-hMSCs可能有助于骨和软骨修复，然而，由于其血管生成潜力，它们也可能为开发组织工程化血管移植物的新方法铺平道路，这些血管移植物在需要缺血组织血管化时是有用的。
Term Amniotic membrane (AM) is a very attractive source of Mesenchymal Stem Cells (MSCs) due to the fact that this fetal tissue is usually discarded without ethical conflicts, leading to high efficiency in MSC recovery with no intrusive procedures. Here we confirmed that term AM, as previously reported in the literature, is an abundant source of hMSCs; in particular we further investigated the AM differentiation potential by assessing whether these cells may also be committed to the angiogenic fate. In agreement with the recommendation of the International Society for Cellular Therapy, the mesenchymal cells herein investigated were named Amniotic Membrane-human Mesenchymal Stromal Cells (AM-hMSC). The recovery of hMSCs and their in vitro expansion potential were greater in amniotic membrane than in bone marrow stroma. At flow cytometry analysis AM-hMSCs showed an immunophenotypical profile, i.e., positive for CD105, CD73, CD29, CD44, CD166 and negative for CD14, CD34, CD45, consistent with that reported for bone marrow-derived MSCs. In addition, amniotic membrane-isolated cells underwent in vitro osteogenic (von Kossa stain), adipogenic (Oil Red-O stain), chondrogenic (collagen type II immunohistochemichal detection) and myogenic (RT-PCR MyoD and Myogenin expression as well as desmin immunohistochemical detection) differentiation. In angiogenic experiments, a spontaneous differentiation into endothelial cells was detected by in vitro matrigel assay and this behaviour has been enhanced through Vascular Endothelial Growth Factor (VEGF) induction. According to these findings, VEGF receptor 1 and 2 (FLT-1 and KDR) were basally expressed in AM-hMSCs and the expression of endothelial-specific markers like FLT-1 KDR, ICAM-1 increased after exposure to VEGF together with the occurrence of CD34 and von Willebrand Factor positive cells. The current study suggests that AM-hMSCs may emerge as a remarkable tool for the cell therapy of multiple diseased tissues. AM-hMSCs may potentially assist both bone and cartilage repair, nevertheless, due to their angiogenic potential, they may also pave the way for novel approaches in the development of tissue-engineered vascular grafts which are useful when vascularization of ischemic tissues is required.